Geebs Coaching

Peer-reviewed study

GLP-1s lower fat, but lean mass still needs attention

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

PeptidesSystematic review and network meta-analysis of randomized trials2026

Source details

PubMed-linked study details.

Authors
Wachiraphansakul et al.
Journal
Diabetes, Obesity and Metabolism. 2026.
Identifiers
PMID 42209204 · DOI 10.1111/dom.70884

Honest limits

What this study does not prove.

This analysis cannot choose a medication or dose for an individual or predict side effects. Those decisions belong in clinician-managed care.

Kris's practical takeaway

Here's what to do with it.

Fat loss can improve while strength, protein intake, and lean-mass monitoring still need attention.

Ways to use it

Safe ways to apply it.

Body composition beats scale-only thinking

Fat loss still needs a strength signal

GLP-1 weight loss still needs strength and nutrition support

Related questions

Questions this research helps answer.

Related guides and studies

FAQ

Quick questions

What is the practical takeaway from this study?

Fat loss can improve while strength, protein intake, and lean-mass monitoring still need attention.

What does this study not prove?

This analysis cannot choose a medication or dose for an individual or predict side effects. Those decisions belong in clinician-managed care.

Weekly Science Drop

Get one useful study each week.

One study, one coaching move, and one honest limit so research turns into action instead of overclaiming.

Weekly Science Drop

Get one useful peptides study breakdown each week, with Kris's practical takeaway and a clear explanation of what the research does and does not prove. No spam, no fake certainty, unsubscribe anytime.